HBM Holdings Limited (HKG:2142)
Hong Kong · Delayed Price · Currency is HKD 14.83
+0.04 (0.27%)
Apr 17, 2026, 2:15 PM HKT
HBM Holdings Revenue
In the year 2025, HBM Holdings had annual revenue of $157.98M USD with 314.63% growth. HBM Holdings had revenue of $56.66M in the half year ending December 31, 2025, with 16.81% growth.
Revenue
$157.98M
Revenue Growth
+314.63%
P/S Ratio
10.05
Revenue / Employee
$580.79K
Employees
272
Market Cap
12.36B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 157.98M | 119.88M | 314.63% |
| Dec 31, 2024 | 38.10M | -51.40M | -57.43% |
| Dec 31, 2023 | 89.50M | 48.84M | 120.13% |
| Dec 31, 2022 | 40.66M | 36.35M | 843.80% |
| Dec 31, 2021 | 4.31M | -9.80M | -69.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.72B |
| Everest Medicines | 1.90B |
| Lepu Biopharma | 1.04B |
| Abbisko Cayman | 681.17M |
| Ascentage Pharma Group International | 638.89M |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |
| Nanjing Leads Biolabs | 197.25M |